All News
Which RA patients are at increased risk of JAKi adverse events? Does disease activity matter?
in the upadacitinib ph3 trials, high disease activity pts had more:
serious infections
HZ
MACE
VTE
Active RA is a massive contributor to many AEs in JAKi pts
#ACR24 ABST1393 @RheumNow https://t.co/DlFf9Sfbja
David Liew drdavidliew ( View Tweet)
Zhang @jeffsparks et al. Even more evidence that MTX does not cause ILD, and in fact prevents ILD, in RA, OR 0.48 in meta-analysis. @RheumNow #ACR24 Abstr#1384 https://t.co/YvQnmmvNjF https://t.co/crYUwHahDb
Links:
Richard Conway RichardPAConway ( View Tweet)
The idea of patient-initiated follow-up for RA is enticing:
patient & physician time is already stretched
minimize unnecessary visits/improve access
but what actually needs to go into the design, to make it safe/workable?
A: plenty.
🇨🇦 pilot underway
#ACR24 ABST1041 @RheumNow https://t.co/03u4bhnQ0v
David Liew drdavidliew ( View Tweet)
STAR trial of GC w/d in RA LDA
SEMIRA of GC w/d controlled RA on Toci
Very slight disease activity increase, but higher flares
No symptomatic adrenal insufficiency, but data of abnormal ACTH stim
No good evidence of steroid w/d symptoms
Beth Wallace
@RheumNow #ACR24 https://t.co/j6UPWlVNIu
Links:
Eric Dein ericdeinmd ( View Tweet)
Serrano-Combarro et al. Case series of upadacitinib in RA-ILD. 18 patients. Report stable/improved dyspnoea and HRCT over 12 months. PFTs shown, relatively stable @RheumNow #ACR24 Abstr#1372 https://t.co/yncy0lPq60 https://t.co/mrDMtEDwUt
Links:
Richard Conway RichardPAConway ( View Tweet)
Great table re:side effects of even low dose steroids in RA
Likely generalizes to other diseases ie PMR, SLE
P in prednisone stands for poison!
#ACR24 @RheumNow https://t.co/0opDEtzm9E
Mike Putman EBRheum ( View Tweet)
Are biosimilar multi-switches an issue?
real world data: DANBIO 🇩🇰
biosimilar to biosimilar switch
having already had a switch prior ('previous ADAo') did not increase cessation
The risk of biosimilar switching on immunogenicity is greatly overstated
#ACR24 ABST1000 @RheumNow https://t.co/1yAfZrrNd0
David Liew drdavidliew ( View Tweet)
Sukumaran et al. Does does of IA steroid matter in knee injection? RCT 30 patients. Triamcinolone. 6-week WOMAC decrease 6% in 10mg, 10% in 20mg , 29% in 40mg @RheumNow #ACR24 Abstr#1186 https://t.co/WUYiEP5dSo
Richard Conway RichardPAConway ( View Tweet)
#1477 🔬Zasocitinib (TYK-2i) shows promise in phase IIb RCT
➡️n=290, randomised to PBO, 5/15/30mg gps
💥30mg group
📉 Rapid skin improvement @ Wk 2
➡️Wk 12 PASI:~2X placebo (-2.5;p=0.004)
🛟Well tolerated
⬆️MDA (28 v. 12.5% p<0.05) promise for other PsA domains
#ACR @RheumNow https://t.co/5GusMlVkQ4
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
T2T approaches in early PsA:
-STAMP trial (open label, multicenter RCT) eval early SEC (300mg+ MTX15+ 80mg steroid injection) vs SoC (MTX25+80mg steroid injection)
-At week 12, 38% pts on SEC vs
17% on SoC achieved ACR50. Also did better on MDA & PASI.
-No significant… https://t.co/MflI3d0FqV https://t.co/RjnzeaTyQK
Links:
Adela Castro AdelaCastro222 ( View Tweet)
At "Envisioning a Steroid Free Future" talk
Angelo Gaffo at the mic: "Are there any situations you would do induction therapy for AAV without steroid?"
John Stone: [pause] "No." 😄
#ACR24 @RheumNow
Mike Putman EBRheum ( View Tweet)
In case you needed more encouragement for recombinant zoster vaccination in RA patients:
it prevents herpes zoster episodes, in the real world.
RA pts in KP system
n=1926 vaccinated matched 1:3 with non-vaccinated
- HZ reduced 60%
- PHN reduced 88%
#ACR24 ABST0977 @RheumNow https://t.co/BryBrlv9K5
David Liew drdavidliew ( View Tweet)
Appreciate the conversation with Dr Ana-Maria Orbai @jhrheumatology on abstract#0600 on bimekizumab PRO data
https://t.co/86J4HWKeIv
@RheumNow #ACR24 https://t.co/QYqj5rKHIH
Links:
Eric Dein ericdeinmd ( View Tweet)
Give a listen to my @RheumNow interview w Josh Hsieh, a rising star at #ACR24, who is presenting his first (of many) research project as a high school sophomore!
His work w @NamrataRheum explores what is known- & not yet known- for cancer survival in RA
https://t.co/boqwpP9CUK https://t.co/UQ37pyvZT6
Eric Dein ericdeinmd ( View Tweet)
Quaack etlal. PreCARA study (vs PARA, historical control). T2T in RA improves fertility - time to pregnancy 84 days vs 196 days. T2T strategy also led to less NSAIDs and prednisolone. @RheumNow #ACR24 Abstr#1647 #ACRbest https://t.co/vYCCUqpCLo https://t.co/PUHJOxgGbL
Links:
Richard Conway RichardPAConway ( View Tweet)
#2282
🔬 Personalised Approach to TNFi in RA
📊 N=50👇; 43 responders
🔑 Findings
💥TNFR2 rs1061622 polymorphism linked to TNFi response
💥 MR/RR alleles ⬆️ 10X odds non-response v. MM allele (OR = 10.1,p=0.04)
🎯Genotyping may guide personalized RA therapy.
#ACR24 @RheumNow https://t.co/MQKZUCEPxj
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
#1330
🔬F-Calprotectin in Early RA
➡️ New-onset RA pts(n=104) had ⬆️ F-calprotectin vs controls(n=50)(71 v. 17µg/g; p<0.001)
🔑Higher F-calprotectin linked to ⬆️ DAS28 & NSAID use
⬇️levels @ 6 months Rx
❓Role of subclinical gut inflammation in early RA
#ACR24 @RheumNow
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Plenary II: pregnancy in RA
When a treat to target approach is used to achieve remission, pregnancy rates nearly similar to general population!
Time to pregnancy less than half that of non-T2T comparators
@RheumNow #ACR24 https://t.co/B9F9M8t9Kt
Links:
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Infertility in women with RA 2x higher
Risk factors
- age
- disease activity
- use of NSAIDs
- use of pred >7.5mg/day
With T2T aiming for remission, fertility improves and becomes similar to the general population
#ACR24 @RheumNow ABST#1647 https://t.co/B2Tx4dju4Z
Jiha Lee JihaRheum ( View Tweet)
#1350
🔬 Microbiome & RA: Impact on Disease Activity & Vascular Function
➡️ Salivary microbiome a/w arterial stiffness (AIx)(p 0.019)
➡️ Stool microbiome a/w DAS28-CRP(p 0.027)
🔴Key taxa👇identified for each; no common taxa for both disease activity & AIx.
#ACR24 @RheumNow https://t.co/54Sumzzd27
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
